Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | TYMP | P19971 | 6/20 | 0.43 |
| ▸ | PNP | P00491 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | G6PD | P11413 | 1/20 | 0.34 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20008064 | 0.72 | ALDH1A1 (0.36) | TYMPALDH1A1CYP2C19 | |
| SCHEMBL17787656 | 0.71 | TYMP (0.38) | TYMPPNPALDH1A1CYP2C19RPS6KA3 | |
| SCHEMBL26980449 | 0.69 | GAA (0.54) | GAATYMPPNPG6PDRPS6KA3 | |
| SCHEMBL17844454 | 0.68 | ALDH1A1 (0.49) | PNPALDH1A1CYP2C19MAPT | |
| SCHEMBL7914803 | 0.68 | ALDH1A1 (0.56) | PNPALDH1A1CYP2C19MAPT | |
| SCHEMBL3982774 | 0.68 | GAA (0.57) | GAATYMPPNPALDH1A1G6PD | |
| SCHEMBL15331802 | 0.67 | TYMP (0.48) | GAATYMPPNPG6PDRPS6KA3 | |
| SCHEMBL8553879 | 0.67 | ALDH1A1 (0.55) | PNPALDH1A1CYP2C19MAPT | |
| SCHEMBL4570273 | 0.66 | ALDH1A1 (0.54) | PNPALDH1A1CYP2C19MEN1KMT2A | |
| SCHEMBL15384307 | 0.66 | MEN1 (0.45) | GAATYMPPNPALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0304004-B1 | Process for the production of sodium purines | BOEHRINGER INGELHEIM KG (DE) | 1993-11-03 | — | — | EP | disclosed |
| CN-1017241-B | PREPARATION OF URACIL COMPOUNDS | SHANDONG XINHUA PHARMACEUTICAL (CN) | 1992-07-01 | — | — | CN | disclosed |
| EP-0221996-B1 | SUBSTITUTED 2,3-DIHYDRO-6-HYDROXY-PYRIMIDO [2,1-f] PURINE-4,8(1H,9H)-DIONES | SCHERING CORPORATION (US) | 1990-08-29 | — | — | EP | disclosed |
| US-4847377-A | ANTIHYPERPROLIFERATIVE SKIN DISEASES | SCHERING CORPORATION (US) | 1989-07-11 | — | — | US | disclosed |
| US-4816458-A | TOPICAL ADMINISTERING | SCHERING CORPORATION (US) | 1989-03-28 | — | — | US | disclosed |
| EP-0304004-A1 | Process for the production of sodium purines | BOEHRINGER INGELHEIM KG (DE) | 1989-02-22 | — | — | EP | disclosed |
| CN-87101334-A | Produce the method for uracil compounds | — | 1988-02-10 | — | — | CN | disclosed |
| EP-0221996-A1 | SUBSTITUTED 2,3-DIHYDRO-6-HYDROXY-PYRIMIDO [2,1-f] PURINE-4,8(1H,9H)-DIONES. | SCHERING CORP (US) | 1987-05-20 | — | — | EP | disclosed |
| EP-0107165-B1 | SUBSTITUTED 9H-8-OXO-PYRIMIDO(2,1-F)PURINE-2,4-DIONES, PROCESS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SCHERING CORPORATION (US) | 1987-04-15 | — | — | EP | disclosed |
| WO-1986006724-A1 | SUBSTITUTED 2,3-DIHYDRO-6-HYDROXY-PYRIMIDO AD2,1-f BD-PURINE-4,8(1H,9H)-DIONES | SCHERING CORPORATION (US) | 1986-11-20 | — | — | WO | disclosed |
| US-4569936-A | Anti-inflammatory substituted 9H-8-oxo-pyrimido[2,1-f]purine-2,4-diones | SCHERING CORPORATION (US) | 1986-02-11 | — | — | US | disclosed |
| EP-0107165-A1 | Substituted 9H-8-oxo-pyrimido(2,1-f)purine-2,4-diones, process for their production and pharmaceutical compositions containing them | SCHERING CORPORATION (US) | 1984-05-02 | — | — | EP | disclosed |